 |
市場調査レポート
商品コード
1566219
ニコチンガムの市場規模、シェア、成長分析、タイプ別、流通チャネル別、地域別 - 産業予測、2024年～2031年Nicotine Gum Market Size, Share, Growth Analysis, By Type (2mg, and 4mg), By Distribution Channel (Supermarkets/hypermarkets, Convenience stores), By Region - Industry Forecast 2024-2031 |
||||||
| ニコチンガムの市場規模、シェア、成長分析、タイプ別、流通チャネル別、地域別 - 産業予測、2024年～2031年 |
|
出版日: 2024年10月01日
発行: SkyQuest
ページ情報: 英文 157 Pages
納期: 3～5営業日
|
- 全表示
- 概要
- 目次
ニコチンガムの世界市場規模は、2022年に13億米ドルと評価され、2023年の13億7,000万米ドルから2031年には21億2,000万米ドルに成長し、予測期間（2024-2031年）のCAGRは5.6％で成長する見通しです。
米国ニコチンガム市場は、FDA認可の禁煙補助剤であり、禁煙を求める個人の顕著な増加により、今後数年間で持続的な成長が見込まれます。このガムは、禁断症状を緩和するためにニコチンパッチと併用したり、必要に応じて強い欲求と闘ったりすることができ、口の粘膜からニコチンを放出し、ニコチンへの衝動を効果的に抑制します。当初はCOVID-19ロックダウンの影響を受けたが、世界保健機関（WHO）や疾病対策予防センター（CDC）などの保健機関が、ウイルスに関連する健康リスクを軽減するために禁煙することの重要性を強調しているため、需要が再燃しています。喫煙による健康への悪影響に対する意識の高まりが、禁煙補助製品の普及にさらに拍車をかけています。喫煙習慣に伴う危険性を認識する喫煙者が増えるにつれ、喫煙欲求を抑える風味豊かで利用しやすい解決策としてのニコチンガムの魅力が市場の成長を促進すると思われます。このような消費者行動の変化は、禁煙を提唱する継続的な公衆衛生キャンペーンとともに、ニコチンガム分野を競争の激しいウェルネス市場において持続的な拡大へと導いています。
目次
イントロダクション
- 調査の目的
- 定義
- 市場範囲
調査手法
- 情報調達
- 二次データソースと一次データソース
- 市場規模予測
- 市場の想定と制限
エグゼクティブサマリー
- 市場概要見通し
- 供給需要動向分析
- セグメント別機会分析
市場力学と見通し
- 市場力学
- 促進要因
- 機会
- 抑制要因
- 課題
- ポーターの分析
主な市場の考察
- 主な成功要因
- 競合の程度
- 主な投資機会
- 市場のエコシステム
- バリューチェーン分析
- 原材料の分析
- 価格分析
- 消費者行動分析
- PESTLE分析
ニコチンガム市場：タイプ別
- 市場概要
- 2mg
- 4mg
ニコチンガム市場：流通チャネル別
- 市場概要
- スーパーマーケット/ハイパーマーケット
- コンビニエンスストア
- 薬局
- オンライン
ニコチンガム市場規模：地域別
- 市場概要
- 北米
- 米国
- カナダ
- 欧州
- ドイツ
- スペイン
- フランス
- 英国
- イタリア
- その他欧州地域
- アジア太平洋地域
- 中国
- インド
- 日本
- 韓国
- その他アジア太平洋地域
- ラテンアメリカ
- ブラジル
- その他ラテンアメリカ地域
- 中東・アフリカ（MEA）
- GCC諸国
- 南アフリカ
- その他中東・アフリカ地域
競合情勢
- 上位5社の比較
- 主要企業の市場ポジショニング（2023年）
- 主な市場企業が採用した戦略
- 市場における最近の活動
- 主要企業の市場シェア（2023年）
主要企業プロファイル
- Johnson & Johnson（US）
- Novartis AG（Switzerland）
- ITC Limited（India）
- Cipla Health Limited（India）
- Perrigo Company Plc（Ireland）
- Teva Canada（Canada）
- Philip Morris International Inc.（US）
- British American Tobacco PLC（UK）
- GlaxoSmithKline plc（UK）
- Novartis Consumer Health（Germany）
- Fertin Pharma（Denmark）
- Alchem International（India）
- Revolymer（UK）
- Pfizer Inc.（US）
- Cambrex Corporation（US）
- Reynolds American（US）
- Takeda Pharmaceutical Company（Japan）
Global Nicotine Gum Market size was valued at USD 1.30 billion in 2022 and is poised to grow from USD 1.37 billion in 2023 to USD 2.12 billion by 2031, growing at a CAGR of 5.6% in the forecast period (2024-2031).
The US nicotine gum market, an FDA-approved smoking cessation aid, is set to experience sustainable growth in the coming years, driven by a notable increase in individuals seeking to quit smoking. This gum, which can be used in conjunction with nicotine patches to alleviate withdrawal symptoms or to combat stronger cravings as needed, releases nicotine through the mouth lining, effectively suppressing the urge for nicotine. Although initially impacted by COVID-19 lockdowns, there has been a resurgence in demand as health organizations like the World Health Organization (WHO) and the Centers for Disease Control and Prevention (CDC) have emphasized the importance of quitting smoking to mitigate health risks associated with the virus. Rising awareness of the detrimental health effects of smoking has further fueled the push for cessation products. As more smokers recognize the dangers associated with their habits, the appeal of nicotine gum as a flavorful, accessible solution to curb cravings will drive market growth. This shift in consumer behavior, along with ongoing public health campaigns advocating for smoking cessation, positions the nicotine gum sector for sustained expansion in the competitive wellness market.
Top-down and bottom-up approaches were used to estimate and validate the size of the Global Nicotine Gum market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.
Global Nicotine Gum Market Segmental Analysis
Global Nicotine Gum Market is segmented on the basis of type, distribution channel, and region. By type, market is segmented into 2mg, and 4mg. By distribution channel, market is segmented into supermarkets/hypermarkets, convenience stores, pharmacies, and online. By region, the market is segmented into North America, Europe, Asia Pacific, Middle East and Africa, and Latin America.
Driver of the Global Nicotine Gum Market
The increasing prevalence of diseases linked to tobacco use, such as lung cancer, heart disease, and respiratory ailments, serves as a significant market driver for the global nicotine gum market. As public awareness of the health risks associated with smoking grows, individuals are seeking effective cessation aids to combat their addiction and safeguard their health. Nicotine gum provides a trusted and convenient method for smokers to manage cravings and reduce withdrawal symptoms, thus promoting healthier lifestyles. Consequently, the escalating global tobacco crisis is intensifying the demand for nicotine replacement therapies, positioning nicotine gum as a crucial solution in public health efforts to reduce smoking-related morbidity and mortality.
Restraints in the Global Nicotine Gum Market
The Global Nicotine Gum market faces significant restraints due to the common adverse reactions associated with its use, which include high blood pressure, rapid heart rate, dizziness, insomnia, and gastrointestinal issues such as nausea and indigestion. These side effects can deter potential users from adopting nicotine gum as a smoking cessation aid, as individuals may be hesitant to experience discomfort or health complications. Additionally, the risk of experiencing prolonged adverse effects from frequent chewing can further discourage usage, ultimately suppressing market growth during the forecast period as consumers exercise caution in seeking alternatives for nicotine replacement therapies.
Market Trends of the Global Nicotine Gum Market
The global nicotine gum market is poised for significant growth in the coming years, driven by heightened health awareness and a collective shift towards healthier lifestyles. Increased government focus on reducing smoking rates through comprehensive tobacco control measures-including bans on advertising, promotion, and the gradual escalation of tobacco taxes-will bolster demand for nicotine replacement therapies. These initiatives, combined with efforts to limit smoking in workplaces and public areas, are expected to not only curtail the prevalence of smoking but also encourage smokers to seek alternatives like nicotine gum, ultimately expanding the market.
Table of Contents
Introduction
- Objectives of the Study
- Definitions
- Market Scope
Research Methodology
- Information Procurement
- Secondary & Primary Data Sources
- Market Size Estimation
- Market Assumptions & Limitations
Executive Summary
- Market Overview Outlook
- Supply Demand Trend Analysis
- Segmental Opportunity Analysis
Market Dynamics & Outlook
- Market Dynamics
- Drivers
- Opportunities
- Restraints
- Challenges
- Porters Analysis
- Competitive rivalry
- Threat of Substitute Products
- Bargaining Power of Buyers
- Threat of New Entrants
- Bargaining Power of Suppliers
Key Market Insights
- Key Success Factor
- Degree Of Competition
- Top Investment Pockets
- Ecosystem Of the Market
- Value Chain Analysis
- Raw Material Analysis
- Pricing Analysis
- Consumer Behaviour Analysis
- PESTLE Analysis
Nicotine Gum Market, By Type
- Market Overview
- 2mg
- 4mg
Nicotine Gum Market, By Distribution Channel
- Market Overview
- Supermarkets/hypermarkets
- Convenience stores
- Pharmacies
- Online
Nicotine Gum Market Size by Region
- Market Overview
- North America
- USA
- Canada
- Europe
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
- Latin America
- Brazil
- Rest of Latin America
- Middle East & Africa (MEA)
- GCC Countries
- South Africa
- Rest of MEA
Competitive Landscape
- Top 5 Player Comparison
- Market Positioning of Key Players, 2023
- Strategies Adopted by Key Market Players
- Recent Activities in the Market
- Key Companies Market Share (%), 2023
Key Company Profiles
- Johnson & Johnson (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Novartis AG (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- ITC Limited (India)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Cipla Health Limited (India)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Perrigo Company Plc (Ireland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Teva Canada (Canada)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Philip Morris International Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- British American Tobacco PLC (UK)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- GlaxoSmithKline plc (UK)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Novartis Consumer Health (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Fertin Pharma (Denmark)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Alchem International (India)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Revolymer (UK)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Pfizer Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Cambrex Corporation (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Reynolds American (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Takeda Pharmaceutical Company (Japan)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
